Pfizer’s troubled McPherson fill-finish plant evacuated again for bomb threat

Pfizer  headquarters logo sign
The site was evacuated last June after another bomb threat was reported. (Pfizer)

Pfizer’s troubled Kansas fill-finish plant was evacuated for the second time in a year after a bomb threat at the manufacturing facility. The site was evacuated last June after another bomb threat was reported.

The McPherson County Sheriff's Office said emergency crews were called to the facility at 9 a.m. Monday, including bomb-sniffing dogs, CBS affiliate KWCH-12 reported. No bomb materials were found on the site and operations at the plant resumed Monday night.

The facility, which is a Hospira legacy plant, has been dogged with regulatory problems. In February, the FDA released a document from the last inspection of the plant that showed it continued to struggle, even repeating issues the agency pointed out in a previous visit.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The eight-page Form 483 from an October 2017 inspection indicated that of 10 observations the FDA noted, four were repeats from issues inspectors had seen in earlier visits. The agency’s frustration over the fact that it has pointed out similar issues at a number of Pfizer's legacy Hospira plants for years is what led the FDA to send Pfizer a scathing warning letter last year.

Pfizer has said it is working to resolve the regulatory issues. The FDA’s concerns have included insufficient investigation of customer complaints and taking weeks to report out-of-specification results for products instead of the required three days.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.